

Secretory phospholipase A₂ type III enhances α -secretase-dependent amyloid precursor protein processing through alterations in membrane fluidity

Xiaoguang Yang,* Wenwen Sheng,^{†,§} Yan He,[§] Jiankun Cui,[†] Mark A. Haidekker,** Grace Y. Sun,^{†,§} and James C-M. Lee^{1,*}

Department of Biological Engineering,* Department of Pathology and Anatomical Sciences,[†] and Department of Biochemistry,[§] University of Missouri, Columbia, MO 65211; and Driftmier Engineering Center,** University of Georgia, Athens, GA 30602

Abstract In the non-amyloidogenic pathway, amyloid precursor protein (APP) is cleaved by α -secretases to produce α -secretase-cleaved soluble APP (sAPP _{α}) with neuroprotective and neurotrophic properties; therefore, enhancing the non-amyloidogenic pathway has been suggested as a potential pharmacological approach for the treatment of Alzheimer's disease. Here, we demonstrate the effects of type III secretory phospholipase A₂ (sPLA₂-III) on sAPP _{α} secretion. Exposing differentiated neuronal cells (SH-SY5Y cells and primary rat neurons) to sPLA₂-III for 24 h increased sAPP _{α} secretion and decreased levels of A β ₁₋₄₂ in SH-SY5Y cells, and these changes were accompanied by increased membrane fluidity. We further tested whether sPLA₂-III-enhanced sAPP _{α} release is due in part to the production of its hydrolyzed products, including arachidonic acid (AA), palmitic acid (PA), and lysophosphatidylcholine (LPC). Addition of AA but neither PA nor LPC mimicked sPLA₂-III-induced increases in sAPP _{α} secretion and membrane fluidity. Treatment with sPLA₂-III and AA increased accumulation of APP at the cell surface but did not alter total expressions of APP, α -secretases, and β -site APP cleaving enzyme. Taken together, these results support the hypothesis that sPLA₂-III enhances sAPP _{α} secretion through its action to increase membrane fluidity and recruitment of APP at the cell surface.—Yang, X., W. Sheng, Y. He, J. Cui, M. A. Haidekker, G. Y. Sun, and J. C-M. Lee. Secretory phospholipase A₂ type III enhances α -secretase-dependent amyloid precursor protein processing through alterations in membrane fluidity. *J. Lipid Res.* 2010. 51: 957–966.

Supplementary key words arachidonic acid • amyloid- β peptide • Alzheimer's disease

This work was supported by the National Institutes of Health Grants IP01 AG18357 and 1R21 NS052385. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health or other granting agencies.

Manuscript received 16 September 2009 and in revised form 5 October 2009.

Published, JLR Papers in Press, October 5, 2009

DOI 10.1194/jlr.M002287

The senile plaque composed of neurotoxic amyloid- β peptide (A β) is a pathologic characteristic of Alzheimer's disease (AD) (1–6). In the amyloidogenic pathway, A β is derived from a proteolytic process of amyloid precursor protein (APP), in which APP is cleaved sequentially by β - and γ -secretases (7). Alternatively, the non-amyloidogenic pathway is mediated by α -secretase, which cleaves between amino acids 16 and 17 within the A β domain. This secretase is a member of the ADAM (a disintegrin and metalloprotease) family and produces a soluble fragment of APP generally regarded as α -secretase-cleaved soluble APP (sAPP _{α}) (8, 9). Due to the neurotrophic and neuroprotective properties of sAPP _{α} (10), increasing the APP processing by α -secretase has been suggested as a new strategy for the treatment of AD (11).

APP is a transmembrane protein, and recent studies show that APP processing can be affected by the local membrane environment. The activity of β -site APP cleaving enzyme (BACE) to produce neurotoxic A β is favorable in lipid rafts, which are highly ordered membrane microdomains enriched in cholesterol, sphingolipids, and saturated phospholipids (12–17). On the other hand, cleavage of APP by α -secretases is known to occur mainly in nonraft domains (18). Therefore, APP processing can be altered

Abbreviations: AA, arachidonic acid; A β , amyloid- β peptide; AD, Alzheimer's disease; ADAM, a disintegrin and metalloprotease; APP, amyloid precursor protein; BACE, β -site APP cleaving enzyme; BCA, bicinchoninic acid; cPLA₂, cytosolic phospholipase A₂; DHA, docosahexaenoic acid; DRM, detergent-resistant membrane; FACS, fluorescence-activated cell sorting; FCVJ, farnesyl-(2-carboxy-2-cyanovinyl)-julolidine; FRAP, fluorescence recovery after photobleaching; iPLA₂, calcium-independent phospholipase A₂; LPC, lysophosphatidylcholine; M β CD, methyl- β -cyclodextrin; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; NMDA, N-methyl D-aspartate; PA, palmitic acid; PLA₂, phospholipase A₂; RA, all-*trans* retinoic acid; sAPP _{α} , α -secretase-cleaved soluble APP; sPLA₂-III, secretory phospholipase A₂ type III.

¹To whom correspondence should be addressed.
e-mail: leejam@missouri.edu

by manipulating membrane lipid composition, such as cholesterol and sphingolipids removals (19–22).

Phospholipases A₂ (PLA₂s) are ubiquitous enzymes responsible for maintenance of phospholipid homeostasis in cell membranes. Aberrant PLA₂ activity has been implicated in neurodegenerative diseases, including AD, Parkinson's disease, ischemia, spinal cord trauma, and head injury (23–26). Among many types of secretory PLA₂s, secretory phospholipase A₂ type III (sPLA₂-III) has been found to express in human neuronal cells and contribute to neuronal differentiation (27). sPLA₂-III from bee venom is highly homologous to the enzymatic-active central s-domain of human sPLA₂-III (28). This protein has been reported to alter cellular membrane properties (29). In this study, we investigate whether sPLA₂-III alters sAPP_α in differentiated neuronal cells, including SH-SY5Y cells and primary rat neurons, and Aβ secretion. In addition, we also examine the effects of its hydrolyzed products, i.e., arachidonic acid (AA), palmitic acid (PA), and lysophosphatidylcholine (LPC), on sAPP_α secretion, membrane fluidity, recruitment of APP to the cell surface, as well as the expressions of α-secretases and BACE.

MATERIALS AND METHODS

Chemicals and reagents

DMEM with high glucose, DMEM/F12 medium (1:1), Ham's F-12 medium, FBS, penicillin, and streptomycin (pen/strep), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were from Invitrogen (Carlsbad, CA). Neurobasal medium, B27, and trypsin-EDTA were obtained from Gibco (Carlsbad, CA). Bee venom sPLA₂-III was from Cayman Chemical (Ann Arbor, MI). AA, LPC, PA, phorbol 12-myristate 13-acetate (PMA), DMSO, all-*trans* retinoic acid, and poly-L-lysine were from Sigma-Aldrich (St. Louis, MO). Farnesyl-(2-carboxy-2-cyanovinyl)-julolidine (FCVJ) was from Dr. Haidekker's Laboratory (University of Georgia) (30).

Cell culture

Human neuroblastoma SH-SY5Y cells (1.0×10^5 cells/well) were seeded into 12-well plates or 1.0×10^6 cells/dish into 60 mm dishes and were cultured in DMEM/F12 medium (1:1) containing 10% FBS. For differentiation, SH-SY5Y cells were exposed to 10 μM all-*trans* retinoic acid for 6 days with change of fresh culture medium every 2 days.

Primary cortical neurons were prepared from embryonic day 17 Sprague-Dawley rats as described previously (31) with slightly modification. In brief, cortical neurons were enzymatically dissociated (0.05% trypsin with EDTA) and dispersed into a single-cell suspension with pasture pipette and seeded onto glass growth chambers and 6-well dishes coated with 50 mg/1 poly-L-lysine. The cells were maintained in neural basal medium with 2% B27, 2 mM glutamine, and 1% pen/strep for 7 days before experiments. All cells were maintained at 37°C in a 5% CO₂ humidified incubator.

Cell viability by MTT test

Cell viability was determined by MTT reduction. Briefly, differentiated SH-SY5Y cells or primary neurons cultured in 12-well plates were treated with different compounds, e.g., sPLA₂-III, AA, LPC, and PA. After treatment, medium was removed and 1 ml of

MTT reagent (0.5 mg/ml) in DMEM was added into each well. Cells were incubated for 4 h at 37°C, and after dissolving formazan crystals with DMSO, absorption at 540 nm was measured.

Characterization of membrane fluidity by fluorescence microscopy of FCVJ-labeled cells

A fluorescent molecular rotor, FCVJ was used to measure the relative membrane fluidity in SH-SY5Y cells. FCVJ was designed to be a more membrane-compatible fluorescent molecular rotor (32) with the quantum yield strongly dependent on the local free volume. A higher fluorescent intensity of FCVJ reflects the intramolecular rotational motions being restricted by a smaller local free volume, indicating a more viscous membrane. Previously, we verified the application of FCVJ for measuring membrane viscosity by comparing the results obtained using FCVJ with those from the technique of fluorescence recovery after photobleaching (30). In this study, we adapted the protocol from Haidekker et al. (32) to fluorescently label cells with FCVJ. Briefly, after undergoing different treatment protocols, e.g., sPLA₂-III, AA, PA, and LPC, SH-SY5Y cells or primary neurons were washed with PBS and incubated in DMEM containing 20% FBS and 1 μM FCVJ for 20 min. Excess FCVJ was removed by washing cells with PBS three times. Fluorescence intensity measurements were performed at room temperature using a Nikon TE-2000 U fluorescence microscope with an oil immersion 60× objective lens. Images were acquired using a CCD camera controlled by a computer running MetaVue imaging software (Universal Imaging, PA). The fluorescence intensities of FCVJ per cell were measured. Background subtraction was done for all images prior to data analysis.

Western blot analysis of sAPP_α released from SH-SY5Y cells and primary neurons

After treating cells with sPLA₂-III or lipid metabolites for 24 h, culture medium was collected and the same volume of the cell lysate from each sample was used for Western blot analysis using β-actin as internal standard. The culture medium was centrifuged at 12,000 *g* for 5 min to remove cell debris, and the same volume of medium from each sample (e.g., 40 μl) was diluted with Laemmli buffer, boiled for 5 min, subjected to electrophoresis in 7.5% SDS-polyacrylamide gels, and transferred to nitrocellulose membranes. Membranes were blocked for 1 h with 5% (w/v) nonfat dry milk in TBS containing 0.1% (v/v) Tween 20 (TBST) and incubated overnight at 4°C in 3% (w/v) BSA with 0.02% (w/v) sodium azide in TBST with a 6E10 monoclonal antibody (1:1,000 dilution; Millipore, Billerica, MA) that recognizes residues 1–17 of the Aβ domain of human sAPP_α or with a rodent specific polyclonal antibody (1:1,000 dilution; Covance, Dedham, MA). Membranes were washed three times during a 15 min period with TBST and incubated with horseradish peroxidase-conjugated goat anti-mouse IgG antibody (1:2,000 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) in 5% (w/v) nonfat dry milk in TBST at room temperature for 1 h. After washing with TBST for three times, the membrane was subjected to SuperSignal West Pico Chemiluminescent detection reagents from Pierce (Rockford, IL) to visualize bands. The protein bands detected on X-ray film were quantified using a computer-driven scanner and Quantity One software (Bio-Rad).

Western blot analysis of APP, ADAM9, ADAM10, ADAM17, and BACE1 in SH-SY5Y cells

After treatments, the protein concentration of the cell lysate was determined by BCA protein assay kit (Pierce Biotechnology) according to the manufacturer's instruction. Equivalent amounts of protein from each sample (e.g., 30 μg) was diluted with Laemmli buffer, boiled for 5 min, subjected to electrophoresis in 7.5%

SDS-polyacrylamide gels, and transferred to nitrocellulose membranes. Membranes were blocked for 1 h with 5% (w/v) nonfat dry milk in TBST and incubated overnight at 4°C in 3% (w/v) BSA with 0.02% (w/v) sodium azide in TBST with 6E10 monoclonal antibody, anti-ADAM9 antibody (1:1,000 dilution; Abcam, Cambridge, MA), anti-ADAM10 antibody (1:1,000 dilution; Millipore), anti-ADAM17 antibody (1:1,000 dilution; Santa Cruz Biotechnology) or anti-BACE1 antibody (1:1,000 dilution; Sigma-Aldrich). Membranes were washed three times during a 15 min period with TBST and incubated with horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit IgG antibody (1:2,000 dilution; Santa Cruz Biotechnology) in 5% (w/v) nonfat dry milk in TBST at room temperature for 1 h. After washing with TBST for three times, the membrane was subjected to SuperSignal West Pico Chemiluminescent detection reagents from Pierce to visualize bands. The protein bands detected on X-ray film were quantified using a computer-driven scanner and Quantity One software (Bio-Rad).

Immunofluorescent staining and assessment of APP at the cell surface of SH-SY5Y cells

SH-SY5Y cells were plated onto cover slips. After differentiation and treatments, cells were fixed in PBS containing 4% paraformaldehyde without prior permeabilization with detergent. After washing three times with PBS, nonspecific binding of antibodies was blocked by 5% goat serum for 1 h at room temperature. Cells were then incubated overnight at 4°C in 3% goat serum with anti-APP mouse antibody (1:200 dilution; Assay Designs, Ann Arbor, MI) that recognizes the N terminus of APP. The cover slips were washed with PBS and incubated for 1 h at room temperature with FITC-labeled goat anti-mouse secondary antibody (1:400) and washed with PBS. Cover slips were then mounted, and fluorescent intensity measurements were performed at room temperature using the Nikon TE-2000 U fluorescence microscope and oil immersion 60× objective lens. Images were acquired using a CCD camera controlled by a computer running MetaVue imaging software (Universal Imaging). The fluorescent intensities per cell area were measured. Background subtraction was done for all images prior to data analysis.

Fluorescence-activated cell sorting analysis of APP at cell surface of SH-SY5Y cells

After differentiation and treatments, SH-SY5Y cells were detached with nonenzymatic cell dissociation solution (Gibco, Carlsbad, CA). The cells were fixed in PBS containing 4% paraformaldehyde without permeabilization. After washing three times with PBS, nonspecific binding of antibodies was blocked by 5% goat serum for 1 h at room temperature. The cells were then incubated for 2 h at room temperature in 3% goat serum with anti-APP mouse antibody (1:200 dilution; Assay Designs) that recognizes the N terminus of APP. After washing with PBS, cells were then incubated for 1 h at room temperature with FITC-labeled goat anti-mouse secondary antibody (1:400) and washed with PBS. Background fluorescence intensity was assessed in the absence of primary antibody. All measurements were performed on a FACScan flow cytometry system (BD Biosciences, San Jose, CA) equipped with an argon laser. The excitation wavelength was 488 nm and emission intensity was detected with a FITC 525/30 nm filter set. A total of 10,000 cells were analyzed from each sample. Curves were generated with CellQuest software (BD Biosciences), and the median values of intensity were measured for data analysis.

Quantification of secreted A β ₁₋₄₂

After treatments, culture medium was collected, supplemented with protease inhibitor cocktail, and centrifuged at 12,000 *g* for 5 min at 4°C to remove cell debris.

An aliquot (100 μ l) of supernatant was used for A β ₁₋₄₂ quantification using an ELISA kit (Invitrogen) following the manufacturer's recommendation. According to the instruction manual, substances including A β ₁₋₁₂, A β ₁₋₂₀, A β ₁₂₋₂₈, A β ₂₂₋₃₅, A β ₁₋₄₀, A β ₁₋₄₃, A β ₄₂₋₁, and APP have no cross-reactivity. The minimum detectable dose of A β ₁₋₄₂ is <1.0 pg/ml. The level of A β ₁₋₄₂ in each sample was measured in duplicates and expressed in pg/ml.

Statistical analysis

Data are presented as mean \pm SD from at least three independent experiments. Comparison between two groups was made with a Student's *t*-test. Comparisons of more than two groups were made with one-way ANOVA, followed by Bonferroni's post hoc tests. Values of *P* < 0.05 are considered to be statistically significant.

RESULTS

Exogenous sPLA₂-III and AA increased sAPP α secretion in neuronal cells

sPLA₂-III hydrolyzes sn-2 fatty acids of phospholipids in cell membranes, resulting in release of PUFAs and lysophospholipids. To test whether fatty acids or lysophospholipids are responsible for the increase in sAPP α secretion and alteration of membrane fluidity, we used AA and LPC as representative polyunsaturated fatty acids and lysophospholipids, respectively. For a negative control, PA, a saturated fatty acid and not likely a hydrolyzed product of sPLA₂-III, was also applied.

Since sPLA₂-III from bee venom is highly homologous to the sPLA₂-III in human (28), sPLA₂-III from bee venom was used to investigate the effect of sPLA₂-III on sAPP α secretion in neuronal cells in relation to membrane fluidity. We first examined the viability of SH-SY5Y cells and primary rat neurons in response to different doses of sPLA₂-III using the MTT test. As shown in Fig. 1, there is a dose-dependent decrease in cell viability upon exposing SH-SY5Y cells and primary neurons to sPLA₂-III for 24 h. Based on these results, subsequent studies used 100 and 500 ng/ml of sPLA₂-III for treating SH-SY5Y cells and 50 and 100 ng for treating primary neurons. Similar approaches were applied to determine the concentrations of AA (Fig. 1B), PA, and LPC (data not shown) for this study. In this study, 1 and 10 μ M of AA (Fig. 1B), 10 and 100 μ M of PA, and 1 and 10 μ M of LPC were used.

Western blot analysis showed that sPLA₂-III and AA increased sAPP α secretion in SH-SY5Y cells in a dose-dependent manner (Fig. 2A). Since it has been reported that PMA, a protein kinase C agonist, increases sAPP α secretion (33–35), treatment with PMA (10 nM) was used as a positive control. However, PA and LPC did not alter sAPP α secretion (Fig. 2A). The increase in sAPP α secretion induced by sPLA₂-III and AA was not due to the change of APP content in cells as shown in Fig. 2B; exposing cells to sPLA₂-III, AA, LPC, and PA for 24 h did not alter total APP expression in SH-SY5Y cells (Fig. 2B). Consistent with the results from SH-SY5Y cells, sPLA₂-III also increased sAPP α secretion in primary rat neurons (Fig. 2C).




Fig. 1. sPLA₂-III and AA on the viability of neuronal cells. MTT test was applied to examine the viability of cells. MTT reduction was determined by absorption at wavelength of 540 nm for differentiated SH-SY5Y cells in medium with 1% FBS treated with sPLA₂-III (A) and AA (B) for 24 h and for primary rat neurons treated with sPLA₂-III (C) for 24 h. Data are expressed as percentages of control and mean ± SD from at least three independent experiments (* *P* < 0.05; ***P* < 0.01).

sPLA₂-III and AA increased membrane fluidity

To study the effects of sPLA₂-III and its hydrolyzed products on membrane fluidity, we applied a fluorescent molecular rotor, FCVJ. As explained in Materials and

Methods, FCVJ integrated into a highly fluidized membrane exhibits lower quantum yield, as reflected by a lower fluorescent intensity. To validate the application of this technique for the measurement of membrane




Fig. 2. sPLA₂-III, AA, PA, and LPC on sAPP_α secretion and total APP expression in neuronal cells. A: Western blot analysis of sAPP_α shows that sPLA₂-III and AA increased sAPP_α secretion to medium from SH-SY5Y cells, but PA and LPC did not. PMA treatment known to increase sAPP_α secretion in cells was used as a positive control. B: Western blot analysis of total APP shows that sPLA₂-III, AA, LPC, and PA did not alter the total APP expressions in SH-SY5Y cells. C: sPLA₂-III increased sAPP_α secretion to medium from primary neurons. Data are expressed as percentages of control and mean ± SD from at least three independent experiments (* *P* < 0.05; ***P* < 0.01).

fluidity in neuronal cells, we exposed cells to ethanol, a compound known to increase membrane fluidity, and measured the fluorescent intensity of FCVJ integrated in cell membranes. Consistent with the notion that ethanol makes phospholipid bilayer membranes become more fluidized, ethanol caused a decrease in fluorescent intensity of FCVJ in SH-SY5Y cell and primary rat neuron membranes (data not shown). After treatment with sPLA₂-III and AA, cells exhibited a lower fluorescent intensity of FCVJ compared with control (Fig. 3A, B), indicating that sPLA₂-III and AA increased membrane fluidity in SH-SY5Y cells. These results are in agreement with the ability for sPLA₂-III to increase membrane fluidity. However, PA and LPC were not capable of increasing membrane fluidity (Fig. 3B). Consistent with the results from SH-SY5Y cells, sPLA₂-III was capable of increasing membrane fluidity in primary rat neurons. Together with the results for sAPP_α secretion, these data suggest that sPLA₂-III and AA increased sAPP_α through their actions to increase membrane fluidity.

sPLA₂-III and AA increased APP at the cell surface of SH-SY5Y cells

There is strong evidence suggesting that the amyloidogenic pathway to generate Aβ occurs preferentially in the intracellular compartments, whereas the non-amyloidogenic pathway for production of sAPP_α preferentially occurs at the plasma membranes (22, 36–42). Based on results of our studies, it is reasonable to hypothesize that sPLA₂-III and AA alter APP metabolism, resulting in an increase of APP at the cell surface of SH-SY5Y cells. To test this hypothesis, we fluorescently labeled the extracellular domain of APP without invoking the procedure for membrane permeabilization. Immunofluorescence microscopy of APP at the cell surface showed that sPLA₂-III enhanced the labeling of APP at the cell surface (Fig. 4A). Quantitative measurement of the fluorescent intensity indicated that both sPLA₂-III and AA increased APP at the membrane surface by ~50%, whereas LPC and PA did not cause any significant changes compared with control (Fig. 4A). Consistent results were also obtained using the technique of fluorescence-activated cell sorting (Fig. 4B).




Fig. 3. Effects of sPLA₂-III, AA, PA, and LPC on neuronal cell membrane fluidity. A: Representative images of SH-SY5Y cells fluorescently labeled with FCVJ. Bar = 20 μm. B: sPLA₂-III and AA increased membrane fluidity in SH-SY5Y cells, as indicated by a decreased in the fluorescent intensity of FCVJ-labeled cells. Treatments with PA and LPC did not affect membrane fluidity of cells. C, Left: Representative images of primary neurons fluorescently labeled with FCVJ. Bar = 20 μm. C, Right: sPLA₂-III increased membrane fluidity in primary neurons, as indicated by a decreased in the fluorescent intensity of FCVJ-labeled cells. Data are expressed as mean ± SD from at least three independent experiments (* *P* < 0.05; ** *P* < 0.01).




Fig. 4. Effects of sPLA₂-III, AA, PA, and LPC on APP accumulation at the cell surface of SH-SY5Y cells. Immunofluorescence microscopy of APP at the cell surface of SH-SY5Y cells was applied. Cells treated with sPLA₂-III, AA, LPC, and PA for 24 h were labeled with anti-APP antibody and FITC-conjugated secondary antibody without the cell permeabilization procedure. Representative images of fluorescently labeled SH-SY5Y cells without treatment (A, top left) and with sPLA₂-III treatment (A, top, middle, and right). Bar = 20 μm. sPLA₂-III and AA increased the APP accumulation at the cell surface, but LPC and PA did not (A, bottom). Representative curves of fluorescence-activated cell sorting after sPLA₂-III treatment (B, top). The median values of curves were used to perform data analysis. sPLA₂-III and AA increased the APP accumulation at the cell surface, but LPC and PA did not (B, bottom). Data are expressed as percentages of control and mean ± SD from at least three independent experiments (* *P* < 0.05).

sPLA₂-III, AA, PA, and LPC did not alter expressions of total α-secretases in SH-SY5Y cells

Incubation of sPLA₂-III and its hydrolytic products for 24 h may change α-secretase expression for release of sAPP_α. Western blot analysis showed that exposure of sPLA₂-III and its hydrolytic products to SH-SY5Y cells for 24 h did not alter the expressions of different isoforms of α-secretases, including ADAM9, ADAM10, and ADAM17 (Fig. 5). These results show that APP (Fig. 2B) and α-secretases expressions were not factors in the increase in sAPP_α secretion in SH-SY5Y cells induced by sPLA₂-III and AA.

sPLA₂-III decreased secretion of Aβ₁₋₄₂ in SH-SY5Y cells

Since sPLA₂-III and AA increase the secretion of sAPP_α, they may decrease the secretion of Aβ₁₋₄₂ in SH-SY5Y cells and primary rat neurons. Figure 6 shows that ELISA measurement of Aβ₁₋₄₂ secreted from SH-SY5Y cells was decreased upon treatment of sPLA₂-III for 24 h. Consistent results were obtained from primary rat neurons (data not shown). On the other hand, AA, LPC, and PA did not induce a significant change in Aβ₁₋₄₂ (data not shown). The decreased in secretion of Aβ₁₋₄₂ was not due to the change in BACE since sPLA₂-III and its hydrolyzed products did not alter the expression of BACE1 in SH-SY5Y cells (Fig. 7).

DISCUSSION

This study demonstrated for the first time the ability of exogenous sPLA₂-III to cause the increase in sAPP_α release from differentiated SH-SY5Y cells and primary neurons. This study further unveiled a special sensitivity of low concentration of AA in mediating the non-amyloidogenic pathway of APP processing and attributed its effect to an increase in membrane fluidity but not protein synthesis.

There is strong evidence that PLA₂, including the group IV cPLA₂ and group IIA sPLA₂, participate in the pathogenesis of AD. Previous studies demonstrated an increase in mRNA expression and immunoreactivity of cPLA₂ (43–45) and sPLA₂-IIA (26) in AD brains. We have also reported that both cPLA₂ and calcium-independent PLA₂ are key enzymes mediating Aβ-induced mitochondrial dysfunction in primary rat astrocytes (46). The role of cPLA₂ in ameliorating cognitive deficits in an AD mouse model was recently demonstrated using cPLA₂ deficient mice cross with APP transgenic mice (47). Most recently, sPLA₂-III has been reported to express in neuronal cells such as peripheral neuronal fibers, spinal dorsal root ganglia neurons, and cerebellar Purkinje cells, and the expression of sPLA₂-III in these cells has been suggested to contribute to neuronal differentiation and neuronal outgrowth (27). Human sPLA₂-III comprises unique N- and C-terminal domains and a central domain, the S domain. The mature




Fig. 5. Effects of sPLA₂-III, AA, PA, and LPC on the expressions of α -secretases in SH-SY5Y cells. Western blot analysis (A) of α -secretases shows that sPLA₂-III, AA, PA, and LPC did not alter the expressions of different isoforms of α -secretases, including ADAM9 (B, top), ADAM10 (B, middle), and ADAM17 (B, bottom). Data are expressed as percentages of control and mean \pm SD from at least three independent experiments.

form of human sPLA₂-III contains only the S domain, which is sufficient for enzymatic function (28, 48, 49). Bee venom sPLA₂-III has high homology with the S domain of human sPLA₂-III (28). In fact, neurotoxicity of sPLA₂-III




Fig. 6. sPLA₂-III decreases A β ₁₋₄₂ release from SH-SY5Y cells. Release of A β ₁₋₄₂ from SH-SY5Y cells was decreased with an increasing dose of sPLA₂-III. Data are expressed as mean \pm SD from three independent experiments (* $P < 0.05$).




Fig. 7. Effects of sPLA₂-III, AA, PA, and LPC on the expressions of BACE1 in SH-SY5Y cells. Western blot analysis shows that sPLA₂-III, AA, PA, and LPC did not alter the expressions of BACE1 in SH-SY5Y cells. Data are expressed as percentages of control and mean \pm SD from at least three independent experiments.

has been attributed to its binding to N-type receptors (50). In earlier studies, sPLA₂-III was shown to induce cell death in primary neuronal cultures through the ability for AA to modulate N-methyl D-aspartate receptors and /or calcium channels and subsequently potentiate glutamate-induced calcium influx (51–54).

APP processing to generate A β is known to depend on cholesterol-enriched lipid rafts (12, 16). A model of membrane compartmentation has been suggested for APP present in two cellular pools, one associated with the cholesterol-enriched lipid rafts where A β is generated and another outside of rafts (i.e., non-raft domains) where α -cleavage occurs (16). Nevertheless, lowering cholesterol by treatment with statins, compounds that inhibit cholesterol synthesis pathway, was found to reduce (16, 20, 55) or enhance A β generation, depending on the condition of the study (56). An epidemiological study indicated that lowering cholesterol is associated with reduced risk for AD (57, 58). One possible explanation for the controversial results is that moderate reduction in cholesterol is associated with a disorganization of detergent-resistant membranes or lipid rafts and allowing more BACE to contact APP, resulting in increased A β generation, whereas a strong reduction of cholesterol inhibits the activities of BACE and γ -secretase, resulting in a decrease in A β generation (12). Consistent with the membrane compartmentation model, treatment with either methyl- β -cyclodextrin or lovastatin to reduce cellular cholesterol resulted in increase in membrane fluidity and an increase in nonamyloidogenic cleavage by α -secretase to produce sAPP α (21). Interestingly, substitution of cholesterol by the steroid 4-cholesten-3-one induces minor change in membrane fluidity and reduces sAPP α secretion, whereas substitution of cholesterol by lanosterol increases membrane fluidity and sAPP α secretion (21). These results suggest reversible effects of cholesterol on the α -secretase activity depending on membrane fluidity (21). These results also suggest that other pharmacological agents capable of altering membrane fluidity can modulate sAPP α secretion. In this study, we demonstrated that sPLA₂-III and its hydrolyzed product AA increased sAPP α secretion and membrane fluidity in SH-SY5Y cells. Our data are consistent with those from

others that sPLA₂-III increased fluidity of hepatic membranes (59) and that AA resulted in increased fluidity of membranes in cultured human umbilical vein, cerebral endothelial cells (60, 61), and hippocampal neurons in vivo (62). Another hydrolyzed product of PLA₂, docosa-hexaenoic acid, has also been demonstrated to increase membrane fluidity and sAPP_α secretion in HEK cells and in neuronal SH-SY5Y-overexpressing APP cells (63). In addition, it has been reported that nonspecific PLA₂ inhibitor partially suppressed muscarinic receptor-stimulated increase in sAPP_α secretion in SH-SY5Y (64).

APP is a transmembrane protein and its internalization from the plasma membrane is regulated by key regulators of endocytosis, such as Rab5, and this process has been found to enhance APP cleavage by β-secretase leading to increased Aβ levels (65). Many studies support the notion that Aβ production occurs in endosomes (22, 38–42). APP lacking its cytoplasmic internalization motif can accumulate at the plasma membrane and undergo cleavage by α-secretase (36, 37). Alternatively, APP internalization can be reduced by lowering cholesterol, which leads to increase in membrane fluidity, APP accumulation at the cell surface, and increased sAPP_α secretion (21). Increased sAPP_α secretion by benzyl alcohol (C₆H₅OH) has also been shown to be associated with increased membrane fluidity, reduced CTF C99, and elevated CTF C83 levels, indicating enhanced α-secretase cleavage of APP, while decreased sAPP_α secretion by Pluronic F68 is associated with decreased membrane fluidity, elevated CTF C99, and reduced CTF C83 levels, indicating enhanced β-secretase cleavage of APP (66). Similar to these studies, our studies show that sPLA₂-III and AA increase in membrane fluidity, APP recruitment to the cell surface, and sAPP_α secretion. Taken together, our data and those from Kojro et al. (21) and Peters et al. (66) support the notion that increasing membrane fluidity, in general, leads to increased APP recruitment to the cell surface and favoring process by α-secretase leading to sAPP_α secretion (Table 1).

Numerous studies have been reported to provide evidence that sAPP_α possesses both neurotrophic and neuroprotective effects. For example, sAPP_α was shown to induce neurite outgrowth in cultured fibroblasts (67,

68), PC cells (69), human neuroblastoma cells (70), and cortical and hippocampal neurons (71–73). Neuroprotective effects of sAPP_α have been shown to increase cortical synaptogenesis (74) and counteract oxidative impairment (75) and hypoglycemia-induced cytotoxicity (76). In addition to the neurotrophic and neuroprotective of sAPP_α, there is evidence that α-secretase cleavage of APP competes and precludes the BACE cleavage, the primary step for production of neurotoxic Aβ (36, 37). We also found that ~3- to 4-fold enhanced sAPP_α secretion in SH-SY5Y cells induced by sPLA₂-III led to a decrease in Aβ₁₋₄₂ generation (Fig. 6). However, ~2-fold enhanced sAPP_α secretion induced by AA did not lead to an observable decrease in Aβ production. In fact, other in vitro studies also showed that reduced secretion of sAPP_α did not result in corresponding increase in Aβ production, and decreased Aβ production did not result in corresponding increase in secretion of sAPP_α (77). Certainly, more systematic studies will be required to further understand this discrepancy.

Increasing production of sAPP_α has been suggested as a potential therapeutic strategy for AD treatment. In this study, we provide evidence that sPLA₂-III and its hydrolyzed product, AA, increase sAPP_α secretion through their effects on membrane fluidity in SH-SY5Y cells. More studies are needed to examine if sAPP_α plays a role in sPLA₂-III-promoted neuronal outgrowth and differentiation. **FIG**

REFERENCES

- Dickson, D. W. 1999. Microglia in Alzheimer's disease and transgenic models. How close the fit? *Am. J. Pathol.* **154**: 1627–1631.
- Frautschy, S. A., F. Yang, M. Irizarry, B. Hyman, T. C. Saido, K. Hsiao, and G. M. Cole. 1998. Microglial response to amyloid plaques in APPsw transgenic mice. *Am. J. Pathol.* **152**: 307–317.
- McGeer, P. L., S. Itagaki, H. Tago, and E. G. McGeer. 1987. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. *Neurosci. Lett.* **79**: 195–200.
- Perlmutter, L. S., E. Barron, and H. C. Chui. 1990. Morphologic association between microglia and senile plaque amyloid in Alzheimer's disease. *Neurosci. Lett.* **119**: 32–36.
- Selkoe, D. J. 2000. The origins of Alzheimer disease: A is for amyloid. *JAMA.* **283**: 1615–1617.
- Stalder, M., A. Phinney, A. Probst, B. Sommer, M. Staufenbiel, and M. Jucker. 1999. Association of microglia with amyloid plaques in brains of APP23 transgenic mice. *Am. J. Pathol.* **154**: 1673–1684.
- Vassar, R. 2004. BACE1: the beta-secretase enzyme in Alzheimer's disease. *J. Mol. Neurosci.* **23**: 105–114.
- Allinson, T. M., E. T. Parkin, A. J. Turner, and N. M. Hooper. 2003. ADAMs family members as amyloid precursor protein alpha-secretases. *J. Neurosci. Res.* **74**: 342–352.
- Esch, F. S., P. S. Keim, E. C. Beattie, R. W. Blacher, A. R. Culwell, T. Oltersdorf, D. McClure, and P. J. Ward. 1990. Cleavage of amyloid beta peptide during constitutive processing of its precursor. *Science.* **248**: 1122–1124.
- Thornton, E., R. Vink, P. C. Blumbergs, and C. Van Den Heuvel. 2006. Soluble amyloid precursor protein alpha reduces neuronal injury and improves functional outcome following diffuse traumatic brain injury in rats. *Brain Res.* **1094**: 38–46.
- Cheng, H., K. S. Vetrivel, P. Gong, X. Meckler, A. Parent, and G. Thinakaran. 2007. Mechanisms of disease: new therapeutic strategies for Alzheimer's disease—targeting APP processing in lipid rafts. *Nat. Clin. Pract. Neurol.* **3**: 374–382.
- Kaether, C., and C. Haass. 2004. A lipid boundary separates APP and secretases and limits amyloid beta-peptide generation. *J. Cell Biol.* **167**: 809–812.

TABLE 1. Summary of the effects of sPLA₂-III, AA, PA, LPC, MβCD, benzyl alcohol (C₆H₅OH), and Pluronic F68 (PF68) on membrane fluidity, accumulation of APP at the cell surface, and secretion of sAPP_α and Aβ

Cell Treatment	Membrane Fluidity	APP at Cell Surface	Secretion of sAPP _α	Aβ
sPLA ₂ -III	↑	↑	↑	↓
AA	↑	↑	↑	NC
LPC	NC	NC	NC	NC
PA	NC	NC	NC	NC
MβCD	↑ ^a	↑ ^a	↑ ^a	↓ ^{a,b}
C ₆ H ₅ OH	↑ ^c	NA	↑ ^c	↓ ^c
PF68	↓ ^c	NA	↓ ^c	↑ ^c

↑ Denotes increase, ↓ denotes decrease, and NC denotes no change. MβCD, methyl-β-cyclodextrin.

^a Results obtained from Kojro et al. (21).

^b Aβ₁₋₄₀.

^c Results obtained from Peters et al. (66).

13. Vetrivel, K. S., H. Cheng, W. Lin, T. Sakurai, T. Li, N. Nukina, P. C. Wong, H. Xu, and G. Thinakaran. 2004. Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes. *J. Biol. Chem.* **279**: 44945–44954.
14. Cordy, J. M., I. Hussain, C. Dingwall, N. M. Hooper, and A. J. Turner. 2003. Exclusively targeting beta-secretase to lipid rafts by GPI-anchor addition up-regulates beta-site processing of the amyloid precursor protein. *Proc. Natl. Acad. Sci. USA.* **100**: 11735–11740.
15. Marlow, L., M. Cain, M. A. Pappolla, and K. Sambamurti. 2003. Beta-secretase processing of the Alzheimer's amyloid protein precursor (APP). *J. Mol. Neurosci.* **20**: 233–239.
16. Ehehalt, R., P. Keller, C. Haass, C. Thiele, and K. Simons. 2003. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. *J. Cell Biol.* **160**: 113–123.
17. Tun, H., L. Marlow, I. Pinnix, R. Kinsey, and K. Sambamurti. 2002. Lipid rafts play an important role in A beta biogenesis by regulating the beta-secretase pathway. *J. Mol. Neurosci.* **19**: 31–35.
18. Reid, P. C., Y. Urano, T. Kodama, and T. Hamakubo. 2007. Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. *J. Cell. Mol. Med.* **11**: 383–392.
19. Sawamura, N., M. Ko, W. Yu, K. Zou, K. Hanada, T. Suzuki, J. S. Gong, K. Yanagisawa, and M. Michikawa. 2004. Modulation of amyloid precursor protein cleavage by cellular sphingolipids. *J. Biol. Chem.* **279**: 11984–11991.
20. Simons, M., P. Keller, B. De Strooper, K. Beyreuther, C. G. Dotti, and K. Simons. 1998. Cholesterol depletion inhibits the generation of beta-amyloid in hippocampal neurons. *Proc. Natl. Acad. Sci. USA.* **95**: 6460–6464.
21. Kojro, E., G. Gimpl, S. Lammich, W. Marz, and F. Fahrenholz. 2001. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. *Proc. Natl. Acad. Sci. USA.* **98**: 5815–5820.
22. von Arnim, C. A., B. von Einem, P. Weber, M. Wagner, D. Schwanzar, R. Spoelgen, W. L. Strauss, and H. Schneckeburger. 2008. Impact of cholesterol level upon APP and BACE proximity and APP cleavage. *Biochem. Biophys. Res. Commun.* **370**: 207–212.
23. Farooqui, A. A., and L. A. Horrocks. 2006. Phospholipase A2-generated lipid mediators in the brain: the good, the bad, and the ugly. *Neuroscientist.* **12**: 245–260.
24. Sun, G. Y., J. Xu, M. D. Jensen, and A. Simonyi. 2004. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases. *J. Lipid Res.* **45**: 205–213.
25. Muralikrishna Adibhatla, R., and J. F. Hatcher. 2006. Phospholipase A2, reactive oxygen species, and lipid peroxidation in cerebral ischemia. *Free Radic. Biol. Med.* **40**: 376–387.
26. Moses, G. S., M. D. Jensen, L. F. Lue, D. G. Walker, A. Y. Sun, A. Simonyi, and G. Y. Sun. 2006. Secretory PLA2-IIA: a new inflammatory factor for Alzheimer's disease. *J. Neuroinflammation.* **3**: 28.
27. Masuda, S., K. Yamamoto, T. Hirabayashi, Y. Ishikawa, T. Ishii, I. Kudo, and M. Murakami. 2008. Human group III secreted phospholipase A2 promotes neuronal outgrowth and survival. *Biochem. J.* **409**: 429–438.
28. Valentin, E., F. Ghomashchi, M. H. Gelb, M. Lazdunski, and G. Lambeau. 2000. Novel human secreted phospholipase A(2) with homology to the group III bee venom enzyme. *J. Biol. Chem.* **275**: 7492–7496.
29. Best, K. B., A. J. Ohran, A. C. Hawes, T. L. Hazlett, E. Gratton, A. M. Judd, and J. D. Bell. 2002. Relationship between erythrocyte membrane phase properties and susceptibility to secretory phospholipase A2. *Biochemistry.* **41**: 13982–13988.
30. Nipper, M. E., S. Majd, M. Mayer, J. C. Lee, E. A. Theodorakis, and M. A. Haidekker. 2008. Characterization of changes in the viscosity of lipid membranes with the molecular rotor FCVJ. *Biochim. Biophys. Acta.* **1778**: 1148–1153.
31. Satoh, T., K. Kosaka, K. Itoh, A. Kobayashi, M. Yamamoto, Y. Shimojo, C. Kitajima, J. Cui, J. Kamins, S. Okamoto, et al. 2008. Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. *J. Neurochem.* **104**: 1116–1131.
32. Haidekker, M. A., T. Ling, M. Anglo, H. Y. Stevens, J. A. Frangos, and E. A. Theodorakis. 2001. New fluorescent probes for the measurement of cell membrane viscosity. *Chem. Biol.* **8**: 123–131.
33. Caporaso, G. L., S. E. Gandy, J. D. Buxbaum, T. V. Ramabhadran, and P. Greengard. 1992. Protein phosphorylation regulates secretion of Alzheimer beta/A4 amyloid precursor protein. *Proc. Natl. Acad. Sci. USA.* **89**: 3055–3059.
34. Slack, B. E., R. M. Nitsch, E. Livneh, G. M. Kunz, Jr., H. Eldar, and R. J. Wurtman. 1993. Regulation of amyloid precursor protein release by protein kinase C in Swiss 3T3 fibroblasts. *Ann. N. Y. Acad. Sci.* **695**: 128–131.
35. Camden, J. M., A. M. Schrader, R. E. Camden, F. A. Gonzalez, L. Erb, C. I. Seye, and G. A. Weisman. 2005. P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing. *J. Biol. Chem.* **280**: 18696–18702.
36. Haass, C., A. Y. Hung, M. G. Schlossmacher, D. B. Teplow, and D. J. Selkoe. 1993. beta-Amyloid peptide and a 3-kDa fragment are derived by distinct cellular mechanisms. *J. Biol. Chem.* **268**: 3021–3024.
37. Koo, E. H., and S. L. Squazzo. 1994. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. *J. Biol. Chem.* **269**: 17386–17389.
38. Cirrito, J. R., J. E. Kang, J. Lee, F. R. Stewart, D. K. Verges, L. M. Silverio, G. Bu, S. Mennerick, and D. M. Holtzman. 2008. Endocytosis is required for synaptic activity-dependent release of amyloid-beta in vivo. *Neuron.* **58**: 42–51.
39. Kinoshita, A., H. Fukumoto, T. Shah, C. M. Whelan, M. C. Irizarry, and B. T. Hyman. 2003. Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. *J. Cell Sci.* **116**: 3339–3346.
40. Rajendran, L., A. Schneider, G. Schlechtingen, S. Weidlich, J. Ries, T. Braxmeier, P. Schwille, J. B. Schulz, C. Schroeder, M. Simons, et al. 2008. Efficient inhibition of the Alzheimer's disease [beta]-secretase by membrane targeting. *Science.* **320**: 520–523.
41. Schobel, S., S. Neumann, M. Hertweck, B. Dislich, P. H. Kuhn, E. Kremmer, B. Seed, R. Baumeister, C. Haass, and S. F. Lichtenthaler. 2008. A novel sorting nexin modulates endocytic trafficking and alpha-secretase cleavage of the amyloid precursor protein. *J. Biol. Chem.* **283**: 14257–14268.
42. Small, S. A., and S. Gandy. 2006. Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis. *Neuron.* **52**: 15–31.
43. Colangelo, V., J. Schurr, M. J. Ball, R. P. Pelaez, N. G. Bazan, and W. J. Lukiw. 2002. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. *J. Neurosci. Res.* **70**: 462–473.
44. Stephenson, D., K. Rash, B. Smalstig, E. Roberts, E. Johnstone, J. Sharp, J. Panetta, S. Little, R. Kramer, and J. Clemens. 1999. Cytosolic phospholipase A2 is induced in reactive glia following different forms of neurodegeneration. *Glia.* **27**: 110–128.
45. Stephenson, D. T., C. A. Lemere, D. J. Selkoe, and J. A. Clemens. 1996. Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. *Neurobiol. Dis.* **3**: 51–63.
46. Zhu, D., Y. Lai, P. B. Shelat, C. Hu, G. Y. Sun, and J. C. Lee. 2006. Phospholipases A2 mediate amyloid-beta peptide-induced mitochondrial dysfunction. *J. Neurosci.* **26**: 11111–11119.
47. Sanchez-Mejia, R. O., J. W. Newman, S. Toh, G.-Q. Yu, Y. Zhou, B. Halabisky, M. Cisse, K. Scarce-Levie, I. H. Cheng, L. Gan, J. J. Palop, J. V. Bonventre, and L. Mucke. 2008. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. *Nat. Neurosci.* **11**: 1311–1318.
48. Murakami, M., S. Masuda, S. Shimbara, S. Bezzine, M. Lazdunski, G. Lambeau, M. H. Gelb, S. Matsukura, F. Kokubu, M. Adachi, et al. 2003. Cellular arachidonate-releasing function of novel classes of secretory phospholipase A2s (groups III and XII). *J. Biol. Chem.* **278**: 10657–10667.
49. Murakami, M., S. Masuda, S. Shimbara, Y. Ishikawa, T. Ishii, and I. Kudo. 2005. Cellular distribution, post-translational modification, and tumorigenic potential of human group III secreted phospholipase A(2). *J. Biol. Chem.* **280**: 24987–24998.
50. Nicolas, J. P., Y. Lin, G. Lambeau, F. Ghomashchi, M. Lazdunski, and M. H. Gelb. 1997. Localization of structural elements of bee venom phospholipase A2 involved in N-type receptor binding and neurotoxicity. *J. Biol. Chem.* **272**: 7173–7181.
51. DeCoster, M. A. 2003. Group III secreted phospholipase A2 causes apoptosis in rat primary cortical neuronal cultures. *Brain Res.* **988**: 20–28.
52. DeCoster, M. A., G. Lambeau, M. Lazdunski, and N. G. Bazan. 2002. Secreted phospholipase A2 potentiates glutamate-induced calcium increase and cell death in primary neuronal cultures. *J. Neurosci. Res.* **67**: 634–645.
53. Kolko, M., M. A. DeCoster, E. B. de Turco, and N. G. Bazan. 1996. Synergy by secretory phospholipase A2 and glutamate on inducing

- cell death and sustained arachidonic acid metabolic changes in primary cortical neuronal cultures. *J. Biol. Chem.* **271**: 32722–32728.
54. Rodriguez De Turco, E. B., F. R. Jackson, M. A. DeCoster, M. Kolk, and N. G. Bazan. 2002. Glutamate signalling and secretory phospholipase A2 modulate the release of arachidonic acid from neuronal membranes. *J. Neurosci. Res.* **68**: 558–567.
 55. Fassbender, K., M. Simons, C. Bergmann, M. Stroick, D. Lutjohann, P. Keller, H. Runz, S. Kuhl, T. Bertsch, K. von Bergmann, et al. 2001. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. *Proc. Natl. Acad. Sci. USA.* **98**: 5856–5861.
 56. Abad-Rodriguez, J., M. D. Ledesma, K. Craessaerts, S. Perga, M. Medina, A. Delacourte, C. Dingwall, B. De Strooper, and C. G. Dotti. 2004. Neuronal membrane cholesterol loss enhances amyloid peptide generation. *J. Cell Biol.* **167**: 953–960.
 57. Simons, M., F. Schwarzler, D. Lutjohann, K. von Bergmann, K. Beyreuther, J. Dichgans, H. Wormstall, T. Hartmann, and J. B. Schulz. 2002. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. *Ann. Neurol.* **52**: 346–350.
 58. Wolozin, B., W. Kellman, P. Ruisseau, G. G. Celesia, and G. Siegel. 2000. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. *Arch. Neurol.* **57**: 1439–1443.
 59. Kameyama, Y., S. Kudo, K. Ohki, and Y. Nozawa. 1982. Differential inhibitory effects by phospholipase A2 on guanylate and adenylate cyclases of Tetrahymena plasma membranes. *Jpn. J. Exp. Med.* **52**: 183–192.
 60. Beck, R., S. Bertolino, S. E. Abbot, P. I. Aaronson, and S. V. Smirnov. 1998. Modulation of arachidonic acid release and membrane fluidity by albumin in vascular smooth muscle and endothelial cells. *Circ. Res.* **83**: 923–931.
 61. Villacara, A., M. Spatz, R. F. Dodson, C. Corn, and J. Bembry. 1989. Effect of arachidonic acid on cultured cerebrovascular endothelium: permeability, lipid peroxidation and membrane "fluidity". *Acta Neuropathol.* **78**: 310–316.
 62. Fukaya, T., T. Gondaira, Y. Kashiya, S. Kotani, Y. Ishikura, S. Fujikawa, Y. Kiso, and M. Sakakibara. 2007. Arachidonic acid preserves hippocampal neuron membrane fluidity in senescent rats. *Neurobiol. Aging.* **28**: 1179–1186.
 63. Kogel, D., E. Copanaki, U. Hartig, S. Bottner, I. Peters, W. E. Muller, and G. Eckert. 2008. Modulation of membrane fluidity by omega 3 fatty acids: enhanced generation of sAPPalpha is required for the neuroprotective effects of DHA. Poster presentation. The 38th Annual Meeting of the Society for Neuroscience.
 64. Cho, H. W., J. H. Kim, S. Choi, and H. J. Kim. 2006. Phospholipase A2 is involved in muscarinic receptor-mediated sAPPalpha release independently of cyclooxygenase or lipoxygenase activity in SH-SY5Y cells. *Neurosci. Lett.* **397**: 214–218.
 65. Grbovic, O. M., P. M. Mathews, Y. Jiang, S. D. Schmidt, R. Dinakar, N. B. Summers-Terio, B. P. Ceresa, R. A. Nixon, and A. M. Cataldo. 2003. Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. *J. Biol. Chem.* **278**: 31261–31268.
 66. Peters, I., U. Igbavboa, T. Schutt, S. Haidari, U. Hartig, X. Rosello, S. Bottner, E. Copanaki, T. Deller, D. Kogel, et al. 2009. The interaction of beta-amyloid protein with cellular membranes stimulates its own production. *Biochim. Biophys. Acta.* **1788**: 964–972.
 67. Bhasin, R., W. E. Van Nostrand, T. Saitoh, M. A. Donets, E. A. Barnes, W. W. Quitschke, and D. Goldgaber. 1991. Expression of active secreted forms of human amyloid beta-protein precursor by recombinant baculovirus-infected insect cells. *Proc. Natl. Acad. Sci. USA.* **88**: 10307–10311.
 68. Saitoh, T., M. Sundsmo, J. M. Roch, N. Kimura, G. Cole, D. Schubert, T. Oltersdorf, and D. B. Schenk. 1989. Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts. *Cell.* **58**: 615–622.
 69. Milward, E. A., R. Papadopoulos, S. J. Fuller, R. D. Moir, D. Small, K. Beyreuther, and C. L. Masters. 1992. The amyloid protein precursor of Alzheimer's disease is a mediator of the effects of nerve growth factor on neurite outgrowth. *Neuron.* **9**: 129–137.
 70. Wang, R., J. Y. Zhang, F. Yang, Z. J. Ji, G. Chakraborty, and S. L. Sheng. 2004. A novel neurotrophic peptide: APP63–73. *Neuroreport.* **15**: 2677–2680.
 71. Araki, W., N. Kitaguchi, Y. Tokushima, K. Ishii, H. Aratake, S. Shimohama, S. Nakamura, and J. Kimura. 1991. Trophic effect of beta-amyloid precursor protein on cerebral cortical neurons in culture. *Biochem. Biophys. Res. Commun.* **181**: 265–271.
 72. Ohsawa, I., C. Takamura, and S. Kohsaka. 1997. The amino-terminal region of amyloid precursor protein is responsible for neurite outgrowth in rat neocortical explant culture. *Biochem. Biophys. Res. Commun.* **236**: 59–65.
 73. Qiu, W. Q., A. Ferreira, C. Miller, E. H. Koo, and D. J. Selkoe. 1995. Cell-surface beta-amyloid precursor protein stimulates neurite outgrowth of hippocampal neurons in an isoform-dependent manner. *J. Neurosci.* **15**: 2157–2167.
 74. Bell, K. F., L. Zheng, F. Fahrenholz, and A. C. Cuello. 2008. ADAM-10 over-expression increases cortical synaptogenesis. *Neurobiol. Aging.* **29**: 554–565.
 75. Mattson, M. P., Z. H. Guo, and J. D. Geiger. 1999. Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism. *J. Neurochem.* **73**: 532–537.
 76. Mattson, M. P., B. Cheng, A. R. Culwell, F. S. Esch, I. Lieberburg, and R. E. Rydel. 1993. Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein. *Neuron.* **10**: 243–254.
 77. Kim, M. L., B. Zhang, I. P. Mills, M. E. Milla, K. R. Brunden, and V. M. Lee. 2008. Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. *J. Neurosci.* **28**: 12052–12061.